Zacks Investment Research upgraded shares of Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) from a sell rating to a hold rating in a research note published on Tuesday.

According to Zacks, “Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates primarily in Ireland, USA and France. Avadel Pharmaceuticals plc, formerly known as Flamel Technologies SA, is headquartered in Lyon, France. “

Several other equities analysts have also weighed in on the company. Ladenburg Thalmann Financial Services increased their price objective on Avadel Pharmaceuticals PLC. from $27.00 to $30.00 in a report on Thursday, September 7th. Langenberg & Company reissued a buy rating and set a $30.00 price objective (up from $27.00) on shares of Avadel Pharmaceuticals PLC. in a report on Thursday, September 7th. Finally, Roth Capital set a $15.00 price objective on Avadel Pharmaceuticals PLC. and gave the company a buy rating in a report on Wednesday, August 9th.

Shares of Avadel Pharmaceuticals PLC. (AVDL) traded up $0.13 during midday trading on Tuesday, reaching $9.23. The company’s stock had a trading volume of 118,180 shares, compared to its average volume of 168,162. Avadel Pharmaceuticals PLC. has a 1-year low of $8.14 and a 1-year high of $12.30. The company has a market capitalization of $367.57, a price-to-earnings ratio of 17.00 and a beta of 1.41. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.01.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.13. Avadel Pharmaceuticals PLC. had a return on equity of 33.92% and a net margin of 44.47%. The business had revenue of $39.68 million during the quarter, compared to analyst estimates of $38.22 million. During the same period in the prior year, the company earned ($0.08) earnings per share. Avadel Pharmaceuticals PLC.’s revenue was up 23.7% compared to the same quarter last year. equities research analysts anticipate that Avadel Pharmaceuticals PLC. will post 0.28 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Avadel Pharmaceuticals PLC. (AVDL) Upgraded to Hold at Zacks Investment Research” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://theolympiareport.com/2017/11/18/avadel-pharmaceuticals-plc-avdl-upgraded-to-hold-at-zacks-investment-research.html.

In related news, Director Craig R. Stapleton bought 20,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were purchased at an average price of $9.52 per share, for a total transaction of $190,400.00. Following the completion of the transaction, the director now directly owns 507,678 shares in the company, valued at approximately $4,833,094.56. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Peter J. Thornton bought 5,155 shares of the company’s stock in a transaction on Thursday, September 21st. The shares were bought at an average price of $9.74 per share, for a total transaction of $50,209.70. Following the transaction, the director now owns 5,155 shares of the company’s stock, valued at $50,209.70. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 46,855 shares of company stock worth $445,058. Company insiders own 5.07% of the company’s stock.

Several large investors have recently bought and sold shares of the business. Janney Montgomery Scott LLC purchased a new stake in shares of Avadel Pharmaceuticals PLC. during the third quarter worth $2,100,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Avadel Pharmaceuticals PLC. during the third quarter worth $184,000. Perceptive Advisors LLC lifted its position in shares of Avadel Pharmaceuticals PLC. by 8.4% during the third quarter. Perceptive Advisors LLC now owns 1,549,005 shares of the company’s stock worth $16,265,000 after acquiring an additional 119,891 shares in the last quarter. Stonepine Capital Management LLC lifted its position in shares of Avadel Pharmaceuticals PLC. by 31.7% during the third quarter. Stonepine Capital Management LLC now owns 985,210 shares of the company’s stock worth $10,345,000 after acquiring an additional 237,347 shares in the last quarter. Finally, Trexquant Investment LP lifted its position in shares of Avadel Pharmaceuticals PLC. by 18.7% during the third quarter. Trexquant Investment LP now owns 36,218 shares of the company’s stock worth $380,000 after acquiring an additional 5,718 shares in the last quarter. Hedge funds and other institutional investors own 69.56% of the company’s stock.

Avadel Pharmaceuticals PLC. Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals PLC. (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.